Afraa Zrieki1, Robert Farinotti, Marion Buyse. 1. Université Paris-sud XI, Faculté de Pharmacie, Laboratoire de Pharmacie Clinique, UPRES EA 2706, Tour D1, 5ème étage, 5 rue Jean-Baptist Clément, Châtenay-Malabry, 92296, France. afraa.zrieki@u-psud.fr
Abstract
PURPOSE: Elevated expression of the ABC transporters P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) seems to correlate with multidrug resistance of cancer cells. In this study we investigated the effect of COX inhibitors in modulating P-gp and BCRP expression and P-gp activity in Caco-2 cells. METHODS: mRNA and protein expression of MDR1 and BCRP were evaluated by real time PCR and western blot respectively. The activity of P-gp was measured by intracellular accumulation of rhodamine123 or 3H-Digoxin. RESULTS: The chronic exposure of Caco-2 to indomethacin heptyl ester (indo HE) (0.4 muM) or nimesulide (10 muM) (selective COX-2 inhibitors) and naproxen (6 muM) (non selective inhibitor COX-1/COX-2) significantly decreased the expression and activity of P-gp. In contrast, the acute treatment by nimesulide and naproxen did not modify these parameters while indo HE treatment (48-72 h) caused a protein decrease and a functional inhibition of P-gp. Unexpectedly, the short-term treatment with naproxen induced an important increase of BCRP expression, but this induction was lost after long-term treatment. No modification of BCRP expression was observed after indo HE or nimesulide treatment. CONCLUSION: Our observations suggest a possible down regulation of P-gp by COX inhibitors, which may enhance the accumulation of chemotherapy agents.
PURPOSE: Elevated expression of the ABC transporters P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) seems to correlate with multidrug resistance of cancer cells. In this study we investigated the effect of COX inhibitors in modulating P-gp and BCRP expression and P-gp activity in Caco-2 cells. METHODS: mRNA and protein expression of MDR1 and BCRP were evaluated by real time PCR and western blot respectively. The activity of P-gp was measured by intracellular accumulation of rhodamine123 or 3H-Digoxin. RESULTS: The chronic exposure of Caco-2 to indomethacin heptyl ester (indo HE) (0.4 muM) or nimesulide (10 muM) (selective COX-2 inhibitors) and naproxen (6 muM) (non selective inhibitor COX-1/COX-2) significantly decreased the expression and activity of P-gp. In contrast, the acute treatment by nimesulide and naproxen did not modify these parameters while indo HE treatment (48-72 h) caused a protein decrease and a functional inhibition of P-gp. Unexpectedly, the short-term treatment with naproxen induced an important increase of BCRP expression, but this induction was lost after long-term treatment. No modification of BCRP expression was observed after indo HE or nimesulide treatment. CONCLUSION: Our observations suggest a possible down regulation of P-gp by COX inhibitors, which may enhance the accumulation of chemotherapy agents.
Authors: Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner Journal: Drug Metab Dispos Date: 2014-09-26 Impact factor: 3.922
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2020-11 Impact factor: 6.447
Authors: Gráinne Dunne; Laura Breen; Denis M Collins; Sandra Roche; Martin Clynes; Robert O'Connor Journal: Invest New Drugs Date: 2010-07-06 Impact factor: 3.850